CN110623984A - Quadruple viable bacteria preparation for treating diarrhea and application thereof - Google Patents
Quadruple viable bacteria preparation for treating diarrhea and application thereof Download PDFInfo
- Publication number
- CN110623984A CN110623984A CN201911003050.4A CN201911003050A CN110623984A CN 110623984 A CN110623984 A CN 110623984A CN 201911003050 A CN201911003050 A CN 201911003050A CN 110623984 A CN110623984 A CN 110623984A
- Authority
- CN
- China
- Prior art keywords
- strain
- percent
- saccharomyces cerevisiae
- preparation
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a tetragenous viable bacteria preparation for treating diarrhea and application thereof, wherein the tetragenous viable bacteria preparation comprises 5-50% of probiotic mixture, 6-10% of xylooligosaccharide and the balance of glucose, and the probiotic mixture comprises animal bifidobacterium freeze-dried powder, lactobacillus paracasei freeze-dried powder, enterococcus faecium freeze-dried powder and saccharomyces cerevisiae freeze-dried powder. The composite live bacterium preparation of bifidobacterium, lactobacillus, enterococcus faecium and saccharomyces cerevisiae is used for treating diarrhea caused by dog intestinal flora imbalance, and has an obvious treatment effect on diarrhea symptoms caused by dog intestinal flora imbalance. The composition can effectively improve the intestinal flora structure, inhibit pathogenic bacteria, increase the intestinal beneficial flora and improve the immunity of the organism so as to achieve the effects of preventing and treating diseases.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to a tetrad viable bacteria preparation for treating diarrhea and application thereof.
Background
The flora balance of the animal intestinal tract has an important influence on the health status of the digestive tract. In the pet market, represented by canines, antibiotics are the predominant drug. Although the development of various pathogenic bacteria such as campylobacter jejuni, escherichia coli, salmonella and other pathogenic bacteria and the symptoms of intestinal flora disturbance caused by some viral diseases are well controlled for a period of time, the symptoms take effect quickly, the defects after the antibiotics are used are gradually shown, such as the generation of drug-resistant pathogenic bacteria and the residue of drugs in livestock products, the antibiotics can also eliminate sensitive beneficial bacteria with the effects of protecting barriers and resisting external attack bacteria, the dysbacteriosis is aggravated, and then a series of typical symptoms of the intestinal flora disturbance such as vomiting, diarrhea, inappetence and the like are generated, and the fungal infection is caused to aggravate the diarrhea. Therefore, the diarrhea-affected dogs need to be treated by the probiotics, and the diarrhea-affected dogs need not to be treated blindly by antibiotics in clinical practice so as to prevent the further aggravation of the disturbance of the flora. And diseases caused by exogenous causes such as iatrogenic and food-borne diseases can be regulated and recovered by the probiotic. With the knowledge of serious disadvantages of antibiotics, probiotics gradually replace antibiotics, have various advantages of no side effect, capability of promoting animal growth and the like, and are widely concerned by people. Meanwhile, the intestinal flora imbalance of the dogs can be caused by exogenous factors such as too fast and too frequent change of diet, improper nutritional structure, environmental stress and the like.
However, the microecological preparation for dogs in the domestic market is irregular at present, and no microecological preparation for dogs is available.
Disclosure of Invention
The invention aims to provide a tetragenous viable bacteria preparation for treating diarrhea and application thereof.
In order to achieve the purpose, the invention provides the following technical scheme: a tetragenous viable bacteria preparation for treating diarrhea comprises 5-50% of probiotic mixture, 6-10% of xylooligosaccharide, and the balance of glucose;
the probiotic mixture comprises animal bifidobacterium freeze-dried powder, lactobacillus paracasei freeze-dried powder, enterococcus faecium freeze-dried powder and saccharomyces cerevisiae freeze-dried powder.
Furthermore, the viable count ratio of the animal bifidobacterium, the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae is 10-20:10-20:1-2: 1-2.
Furthermore, the viable count of the bifidobacterium animalis B1014 strain is more than or equal to 2.0 multiplied by 109CFU/g, the viable count of the lactobacillus paracasei L1056 strain is more than or equal to 2.0 multiplied by 109CFU/g, the viable count of the enterococcus faecium EF1012 strain is more than or equal to 2.0 multiplied by 108CFU/g, the number of viable bacteria of the saccharomyces cerevisiae S1072 strain is more than or equal to 2.0 multiplied by 108CFU/g。
Further, the survival rate of the strains is higher than 70 percent when the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae are cultured in gastric acid with the pH value of 3.0 for 4 hours; the survival rate of the bifidobacterium animalis strain cultured in gastric acid with the pH value of 3.0 for 4 hours is 58.3 percent, the survival rate of the bifidobacterium animalis strain cultured in 0.3 percent of No. 3 bile salt for 4 hours is higher than 50 percent, and the survival rate of the lactobacillus paracasei strain cultured in 0.3 percent of No. 3 bile salt for 2 hours is higher than 30 percent.
The invention also discloses an application of the tetrad viable bacteria preparation for treating diarrhea, which is characterized in that: the live tetranection preparation is used for treating diarrhea caused by dog intestinal flora imbalance.
Compared with the prior art, the invention has the beneficial effects that: the composite live bacterium preparation of bifidobacterium, lactobacillus, enterococcus faecium and saccharomyces cerevisiae is used for treating diarrhea caused by dog intestinal flora imbalance, the preparation has an obvious treatment effect on diarrhea symptoms caused by dog intestinal flora imbalance, and the bifidobacterium, the lactobacillus, the enterococcus faecium and the saccharomyces cerevisiae can effectively improve the intestinal flora structure, inhibit pathogenic bacteria and improve the immunity of organisms so as to achieve the effects of preventing and treating diseases.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
A tetragenous viable bacteria preparation for treating diarrhea comprises 5% of probiotic mixture, 6% of xylo-oligosaccharide and the balance of glucose;
the probiotic mixture comprises animal Bifidobacterium lyophilized powder, Lactobacillus paracasei lyophilized powder, enterococcus faecium lyophilized powder and Saccharomyces cerevisiae lyophilized powder.
The viable count ratio of the bifidobacterium animalis, the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae is 10:10:1: 1.
The number of viable bacteria of Bifidobacterium animalis B1014 strain is not less than 2.0 × 109CFU/g, the viable count of lactobacillus paracasei L1056 strain is more than or equal to 2.0 multiplied by 109CFU/g, the viable count of enterococcus faecium EF1012 strain is more than or equal to 2.0 multiplied by 108CFU/g, the number of viable bacteria of saccharomyces cerevisiae S1072 strain is more than or equal to 2.0 multiplied by 108CFU/g。
The survival rate of the strains is higher than 70 percent when the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae are cultured in gastric acid with the pH value of 3.0 for 4 hours; the survival rate of the bifidobacterium animalis strain cultured in gastric acid with the pH value of 3.0 for 4 hours is 58.3 percent, the survival rate of the bifidobacterium animalis strain and saccharomyces cerevisiae cultured in 0.3 percent of No. 3 bile salt for 4 hours is higher than 50 percent, and the survival rate of the lactobacillus paracasei and enterococcus faecium cultured in 0.3 percent of No. 3 bile salt for 2 hours is higher than 30 percent.
The application of a tetrad viable bacteria preparation for treating diarrhea is characterized in that: the live tetranection preparation is used for treating diarrhea caused by dog intestinal flora imbalance.
Example 2
A tetragenous viable bacteria preparation for treating diarrhea comprises 50% of probiotic mixture, 10% of xylo-oligosaccharide and the balance of glucose;
the probiotic mixture comprises animal bifidobacterium freeze-dried powder, lactobacillus paracasei freeze-dried powder, enterococcus faecium freeze-dried powder and saccharomyces cerevisiae freeze-dried powder.
The viable count ratio of the bifidobacterium animalis, the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae is 5:5:1: 1.
The number of viable bacteria of Bifidobacterium animalis B1014 strain is not less than 2.0 × 109CFU/g, the viable count of lactobacillus paracasei L1056 strain is more than or equal to 2.0 multiplied by 109CFU/g, the viable count of enterococcus faecium EF1012 strain is more than or equal to 2.0 multiplied by 108CFU/g, the number of viable bacteria of saccharomyces cerevisiae S1072 strain is more than or equal to 2.0 multiplied by 108CFU/g。
The survival rate of the strains is higher than 70 percent when the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae are cultured in gastric acid with the pH value of 3.0 for 4 hours; the survival rate of the bifidobacterium animalis strain cultured in gastric acid with the pH value of 3.0 for 4 hours is 58.3 percent, the survival rate of the bifidobacterium animalis strain and saccharomyces cerevisiae cultured in 0.3 percent of No. 3 bile salt for 4 hours is higher than 50 percent, and the survival rate of the lactobacillus paracasei and enterococcus faecium cultured in 0.3 percent of No. 3 bile salt for 2 hours is higher than 30 percent.
The application of a tetrad viable bacteria preparation for treating diarrhea is characterized in that: the live tetranection preparation is used for treating diarrhea caused by dog intestinal flora imbalance.
Example 3
A tetragenous viable bacteria preparation for treating diarrhea comprises 25% of probiotic mixture, 8% of xylo-oligosaccharide and the balance of glucose;
the probiotic mixture comprises animal Bifidobacterium lyophilized powder, Lactobacillus paracasei lyophilized powder, enterococcus faecium lyophilized powder and Saccharomyces cerevisiae lyophilized powder.
The viable count ratio of the bifidobacterium animalis, the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae is 15:15:2: 2.
The number of viable bacteria of Bifidobacterium animalis B1014 strain is not less than 2.0 × 109CFU/g, the viable count of lactobacillus paracasei L1056 strain is more than or equal to 2.0 multiplied by 109CFU/g, the viable count of enterococcus faecium EF1012 strain is more than or equal to 2.0 multiplied by 108CFU/g, the number of viable bacteria of saccharomyces cerevisiae S1072 strain is more than or equal to 2.0 multiplied by 108CFU/g。
The survival rate of the strains is higher than 70 percent when the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae are cultured in gastric acid with the pH value of 3.0 for 4 hours; the survival rate of the bifidobacterium animalis strain cultured in gastric acid with the pH value of 3.0 for 4 hours is 58.3 percent, the survival rate of the bifidobacterium animalis strain and saccharomyces cerevisiae cultured in 0.3 percent of No. 3 bile salt for 4 hours is higher than 50 percent, and the survival rate of the lactobacillus paracasei and enterococcus faecium cultured in 0.3 percent of No. 3 bile salt for 2 hours is higher than 30 percent.
The application of a tetrad viable bacteria preparation for treating diarrhea is characterized in that: the live tetranection preparation is used for treating diarrhea caused by dog intestinal flora imbalance.
Example 4
The four bacterial strains of the quadruple viable bacteria preparation provided by the invention have the characteristics of acid resistance and bile salt resistance
(1) Study on acid resistance and bile salt resistance of bifidobacterium: adding 5ml of sterile water into 1 strain slant test tube, washing slant bacterial colonies, mixing uniformly, inoculating into shake flask culture medium (the mass percentage of each raw material in the shake flask culture medium is 1.0% of glucose, 1.0% of yeast extract powder, 0.5% of peptone, 0.5% of tryptone, 0.05% of L-cysteine hydrochloride and 4% of trace salt) according to 1%, adjusting pH value to 7.4, sterilizing at 115 ℃ for 20min, and standing and culturing at 37 ℃ for 14-16 h;
acid resistance characteristic study: adding the bacterial liquid into the artificial gastric juice with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
Study of bile salt resistance: adding the bacterial liquid into 0.3% artificial intestinal juice with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
(2) The acid and bile salt resistance of lactobacillus is researched: adding 5ml of sterile water into 1 strain slant test tube, washing slant bacterial colonies, mixing uniformly, inoculating into shake flask culture medium (the mass percentage of each raw material in the shake flask culture medium is 1.0% of glucose, 1.0% of yeast extract powder, 0.5% of peptone, 0.5% of tryptone, 0.05% of L-cysteine hydrochloride and 4% of trace salt) according to 1%, and performing static culture at 37 ℃ for 14-16 h;
acid resistance characteristic study: adding the bacterial liquid into the artificial gastric juice with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
Study of bile salt resistance: adding the bacterial liquid into 0.3% artificial intestinal liquid with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
(3) The research on the acid and bile salt resistance of enterococcus faecium comprises the following steps: adding 5ml of sterile water into 1 strain slant test tube, washing slant bacterial colonies, mixing uniformly, inoculating into shake flask culture medium (the mass percentage of each raw material in the shake flask culture medium is 1.0% of glucose, 1.0% of yeast extract powder, 0.5% of peptone, 0.5% of tryptone and 4% of trace salt, adjusting pH value to 7.0, sterilizing at 115 ℃ for 20min, and reserving) according to 1%, and shake-culturing at 37 ℃ and 150r/min for 12-14 h;
acid resistance characteristic study: adding the bacterial liquid into the artificial gastric juice with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
Study of bile salt resistance: adding the bacterial liquid into 0.3% artificial intestinal liquid with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
(4) Research on acid resistance and bile salt resistance of saccharomyces cerevisiae: adding 5ml of sterile water into 1 strain slant test tube, washing slant bacterial colonies, mixing uniformly, inoculating into shake flask culture medium (the mass percentage of each raw material in the shake flask culture medium is 1.0% of glucose, 1.0% of yeast extract powder, 0.5% of peptone, 0.5% of tryptone and 4% of trace salt, adjusting pH value to 6.5, sterilizing at 115 ℃ for 20min, and reserving) according to 1%, and shake-culturing at 32 ℃ and 220r/min for 12-14 h;
acid resistance characteristic study: adding the bacterial liquid into the artificial gastric juice with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
Study of bile salt resistance: adding the bacterial liquid into 0.3% artificial intestinal liquid with the inoculation amount of 10%, standing and culturing at 37 ℃, and sampling for 0, 1, 2 and 4 hours respectively to determine the survival rate of the bacterial strain.
The formula of the trace salt is as follows: from 0.2g/LCaCl2，0.48g/LMgSO4，10g/LNaHCO3，1.0g/L KH2PO4，1.0g/LK2HPO4And 2.0 g/LNaCl;
the results of the acid resistance study of the four strains are shown in table 1, and table 1 shows the results after the artificial gastric juice treatment.
TABLE 1 results of artificial gastric juice treatment
The experimental results in table 1 show that lactobacillus, enterococcus faecium and saccharomyces cerevisiae have good gastric acid resistance, and the survival rate of lactobacillus, enterococcus faecium and saccharomyces cerevisiae is still higher than 70% when cultured in gastric acid with the pH of 3.0 for 4 hours. The gastric acid resistance of bifidobacterium is slightly poor, but the survival rate of bifidobacterium reaches 58.3 percent when the bifidobacterium is cultured in gastric acid with the pH of 3.0 for 4 hours. The four strains are shown to have better gastric acid tolerance characteristics and can survive in animal intestinal tracts.
The results of the study on the bile salt resistance of the four strains are shown in Table 2, and the Table 2 shows the treatment results of the artificial intestinal juice (containing bile salts).
TABLE 2 results of treatment of artificial intestinal fluids (containing bile salts)
As can be seen from the test results in Table 2, the survival rate of the strain was higher than 50% when Bifidobacterium and Saccharomyces cerevisiae were cultured in 0.3% of bile salt No. 3 for 4 hours. When the lactobacillus and the enterococcus faecium are cultured in 0.3 percent of No. 3 bile salt for 2 hours, the survival rate of the strain is higher than 30 percent, which shows that the effect of the bifidobacterium and the saccharomyces cerevisiae for resisting the bile salt is better, and the effect of the lactobacillus and the enterococcus faecium for resisting the bile salt is slightly worse.
Example 5: clinical trial of tetrad viable bacteria preparation for treating diarrhea
The clinical test is carried out in 240 cases. Indications are as follows: diarrhea caused by intestinal dysbacteriosis, wherein 200 cases of the treatment group and 40 cases of the control group (20 cases of the negative control group and 20 cases of the blank control group) are included. The diarrhea case characteristics of the selected dogs: loose stool and jet-shaped loose stool appear, and the defecation frequency is increased; debilitation in different degrees, and reduced alertness; anorexia, vomiting response; the main characteristic is the excretion of excrement.
The administration scheme is as follows: treatment groups: 1g of small dogs (below 10 kg), 2g of medium dogs (10-20kg) and 3g of large dogs (above 20kg), wherein the doses of the first medicament are doubled after the continuous use for 7 days, and the doses are respectively 1 time in the morning and at night; negative (antibiotic) control group: norfloxacin nicotinate (antibiotic) treatment, in norfloxacin, of dogs at 16 mg/kg/time, 1 each in the morning and evening daily for 3 consecutive days; blank control group: no medication was used. The treatment effect of the quadruple viable bacteria preparation is investigated by observing the clinical symptoms and the fecal state of the test dog and detecting fecal microorganisms of the test dog.
The clinical observations and statistics of treatment in the treatment group, blank control group and negative control group are shown in table 3, and are as follows:
TABLE 3 treatment profiles of clinical trials
| Group/therapeutic Effect | Blank control group | Negative control group | Treatment group |
| Effective (example) | 15 | 18 | 191 |
| Relapse (example) | 1 | 2 | 4 |
| Invalid (example) | 4 | 0 | 5 |
| Percent cure rate/%) | 75％ | 90％ | 95.5％ |
| Non efficiency/%) | 20％ | 0 | 2.5％ |
From table 3, it can be seen that the cure rate of the four-combined live bacteria preparation treatment group is as high as 95%, which is higher than the cure rate of the blank control group and the negative control group. The clinical treatment effect of the tetragenous viable bacteria preparation is good, and dogs recovered in the test period have good spirit, strong appetite, normal skin color of fur, normal color and form of defecation and urination and no other abnormal clinical symptoms. The microecological preparation can increase beneficial bacteria, maintain the balance of intestinal flora, and prevent intestinal mucosa from being invaded by pathogenic bacteria, so that diarrhea dogs are not easy to relapse after recovery.
Table 4 shows the viable bacteria count of each strain in dog feces, which is shown in the following table:
TABLE 4 viable count results (logcfu/g) of various dog fecal strains (X + -SD, n is 20 or more)
Note: in table 4, "+" indicates significant difference (P <0.05), "+" indicates significant difference (P <0.01), and it can be seen from table 4 that the numbers of viable bacteria of the respective bacterial groups in feces of the dogs in each group before treatment were substantially the same, and there was no significant difference, while there was a more significant change in the respective bacterial groups in each group after treatment. Wherein the enterococcus is: the treatment group (8.37 +/-0.58) is higher than the negative control group (7.50 +/-0.77) and the blank control group (7.81 +/-0.93); and (3) lactobacillus: the treatment group (7.47 +/-0.70) is obviously higher than the negative control group (6.45 +/-0.56) and the blank control group (6.89 +/-0.67); bifidobacteria: the treatment group (6.47 +/-0.69) is obviously higher than the negative control group (5.81 +/-0.58) and the blank control group (6.18 +/-0.81), and the difference of the statistical examination is very significant; in the enterobacter bacteria count, the enterobacter bacteria count of the negative control group (5.02 +/-0.66) is the lowest, and the difference among other groups is not significant. Research shows that the tetrad live bacteria preparation for treating the dog has a certain inhibiting effect on pathogenic bacteria, can effectively treat diarrhea, help the intestinal tracts of the dogs to supplement the probiotics, promote the proliferation of the probiotics and be beneficial to maintaining the balance of the flora in the body. Although the antibiotics have good inhibition effect on enterobacteria, sensitive beneficial bacteria with protective barriers and external attack bacteria antagonism can be eliminated, the imbalance of canine intestinal flora is aggravated, and the healthy growth of the canine is not facilitated. Therefore, the tetragenous viable bacteria preparation provided by the invention can effectively treat diarrhea, inhibit the growth of intestinal pathogenic bacteria, maintain the balance of intestinal flora and improve the immunity of organisms.
The composite live bacterium preparation of bifidobacterium, lactobacillus, enterococcus faecium and saccharomyces cerevisiae has the effects of improving the micro-ecological environment of animal intestinal tracts and increasing beneficial flora in the intestinal tracts, is used for treating diarrhea caused by canine intestinal flora imbalance, has an obvious treatment effect on diarrhea symptoms caused by canine intestinal flora imbalance, and can effectively improve the intestinal flora structure, inhibit pathogenic bacteria and improve the immunity of organisms so as to achieve the effects of preventing and treating diseases.
Although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes in the embodiments and/or modifications of the invention can be made, and equivalents and modifications of some features of the invention can be made without departing from the spirit and scope of the invention.
Claims (5)
1. A tetrad viable bacteria preparation for treating diarrhea is characterized in that: comprises 5-50% of probiotic mixture, 6-10% of xylo-oligosaccharide and the balance of glucose;
the probiotic mixture comprises animal bifidobacterium freeze-dried powder, lactobacillus paracasei freeze-dried powder, enterococcus faecium freeze-dried powder and saccharomyces cerevisiae freeze-dried powder.
2. The live tetranection preparation for treating diarrhea according to claim 1, wherein: the viable count ratio of the bifidobacterium animalis, the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae is 10-20:10-20:1-2: 1-2.
3. The live tetranection preparation for treating diarrhea according to claim 1, wherein: the viable count of the bifidobacterium animalis B1014 strain is more than or equal to 2.0 multiplied by 109CFU/g, the viable count of the lactobacillus paracasei L1056 strain is more than or equal to 2.0 multiplied by 109CFU/g, the viable count of the enterococcus faecium EF1012 strain is more than or equal to 2.0 multiplied by 108CFU/g, the number of viable bacteria of the saccharomyces cerevisiae S1072 strain is more than or equal to 2.0 multiplied by 108CFU/g。
4. The live tetranection preparation for treating diarrhea according to claim 1, wherein: the survival rate of the strains is higher than 70 percent when the lactobacillus paracasei, the enterococcus faecium and the saccharomyces cerevisiae are cultured in gastric acid with the pH value of 3.0 for 4 hours; the survival rate of the bifidobacterium animalis strain cultured in gastric acid with the pH value of 3.0 for 4 hours is 58.3 percent, the survival rate of the bifidobacterium animalis strain cultured in 0.3 percent of No. 3 bile salt for 4 hours is higher than 50 percent, and the survival rate of the lactobacillus paracasei strain cultured in 0.3 percent of No. 3 bile salt for 2 hours is higher than 30 percent.
5. Use of a live tetra-bacterial formulation according to claim 1 for the treatment of diarrhoea, wherein: the live tetranection preparation is used for treating diarrhea caused by dog intestinal flora imbalance.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911003050.4A CN110623984A (en) | 2019-10-22 | 2019-10-22 | Quadruple viable bacteria preparation for treating diarrhea and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911003050.4A CN110623984A (en) | 2019-10-22 | 2019-10-22 | Quadruple viable bacteria preparation for treating diarrhea and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110623984A true CN110623984A (en) | 2019-12-31 |
Family
ID=68977108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911003050.4A Pending CN110623984A (en) | 2019-10-22 | 2019-10-22 | Quadruple viable bacteria preparation for treating diarrhea and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110623984A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113430150A (en) * | 2021-08-11 | 2021-09-24 | 真爱生命生物技术(重庆)有限公司 | Probiotics and application thereof |
| CN114009586A (en) * | 2021-11-19 | 2022-02-08 | 广东容大生物股份有限公司 | Development and application of composite probiotic preparation with high intestinal tract colonization rate |
| CN114908019A (en) * | 2022-05-31 | 2022-08-16 | 西南民族大学 | Enterococcus faecium composite microbial inoculum and compounding method and application thereof |
| CN115044515A (en) * | 2022-07-11 | 2022-09-13 | 杭州思我特农业科技有限公司 | Composite probiotics for resisting pet diarrhea and application thereof |
| CN117327632A (en) * | 2023-12-01 | 2024-01-02 | 四川厌氧生物科技有限责任公司 | Bifidobacterium animalis and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN107058158A (en) * | 2016-12-22 | 2017-08-18 | 内蒙古和美科盛生物技术有限公司 | A kind of dog immunity that improves reduces the compound probiotic agent and its preparation and application of diarrhea disease percentage |
| CN108641991A (en) * | 2018-07-11 | 2018-10-12 | 江苏恒丰强生物技术有限公司 | A kind of composite viable bacteria preparation and preparation method and its application |
-
2019
- 2019-10-22 CN CN201911003050.4A patent/CN110623984A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104522648A (en) * | 2014-12-18 | 2015-04-22 | 杭州龙达新科生物制药有限公司 | Tetragenus probiotic preparation and application thereof |
| CN107058158A (en) * | 2016-12-22 | 2017-08-18 | 内蒙古和美科盛生物技术有限公司 | A kind of dog immunity that improves reduces the compound probiotic agent and its preparation and application of diarrhea disease percentage |
| CN108641991A (en) * | 2018-07-11 | 2018-10-12 | 江苏恒丰强生物技术有限公司 | A kind of composite viable bacteria preparation and preparation method and its application |
Non-Patent Citations (4)
| Title |
|---|
| 刘策等: "宠物食品添加剂及其研究进展", 《山东农业科学》 * |
| 孙雯娟等: "益生菌制剂的发展现状与临床应用进展", 《中国医院药学杂志》 * |
| 张高武: "双歧杆菌、乳酸杆菌、粪链球菌和酵母菌符合活菌制剂", 《HTTPS://WWW.CLOUDVET.ORG/MAPI/ARTICLE/366》 * |
| 李华军等主编: "《健康之星：双歧杆菌》", 31 May 2016, 辽宁科学技术出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113430150A (en) * | 2021-08-11 | 2021-09-24 | 真爱生命生物技术(重庆)有限公司 | Probiotics and application thereof |
| CN114009586A (en) * | 2021-11-19 | 2022-02-08 | 广东容大生物股份有限公司 | Development and application of composite probiotic preparation with high intestinal tract colonization rate |
| CN114908019A (en) * | 2022-05-31 | 2022-08-16 | 西南民族大学 | Enterococcus faecium composite microbial inoculum and compounding method and application thereof |
| CN114908019B (en) * | 2022-05-31 | 2023-05-09 | 西南民族大学 | Enterococcus faecium compound microbial inoculum, compounding method and application thereof |
| CN115044515A (en) * | 2022-07-11 | 2022-09-13 | 杭州思我特农业科技有限公司 | Composite probiotics for resisting pet diarrhea and application thereof |
| CN115044515B (en) * | 2022-07-11 | 2024-04-16 | 杭州思我特农业科技有限公司 | Composite probiotics for resisting pet diarrhea and application thereof |
| CN117327632A (en) * | 2023-12-01 | 2024-01-02 | 四川厌氧生物科技有限责任公司 | Bifidobacterium animalis and application thereof |
| CN117327632B (en) * | 2023-12-01 | 2024-02-13 | 四川厌氧生物科技有限责任公司 | Bifidobacterium animalis and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110623984A (en) | Quadruple viable bacteria preparation for treating diarrhea and application thereof | |
| Guo et al. | Effects of long-term Bacillus subtilis CGMCC 1.921 supplementation on performance, egg quality, and fecal and cecal microbiota of laying hens | |
| JP4623896B2 (en) | Bacterial strains, processed plant extracts and probiotic compositions used in humans and animals | |
| JP5830084B2 (en) | Method of using Bacillus subtilis strains for the prevention and treatment of gastrointestinal conditions | |
| EP4252554A1 (en) | Application of lactobacillus paracasei et-22 in improving intestinal bacterial infection resistance and intestinal immunity | |
| CN111956671A (en) | Composite probiotics for treating helicobacter pylori infection | |
| US20230248788A1 (en) | Compositions and related methods for supporting companion animals with gastrointestinal disorders | |
| CN112471353A (en) | Long-acting symbiotic composite liquid microecological preparation for poultry feeding and preparation method thereof | |
| CN117568211A (en) | Lactobacillus plantarum GOLDGUT-LP618 with salmonella infection resistance function and application thereof | |
| CN114052116B (en) | Probiotic plant extract compound biological agent and preparation method and application thereof | |
| CN116200305A (en) | Enterococcus durans strain with anti-inflammatory property, culture method and application | |
| CN113575764B (en) | Saccharomyces cerevisiae culture and application thereof | |
| CN112795508B (en) | Enterococcus faecium YQH2 and application thereof | |
| WO2022035082A1 (en) | Lactic acid bacteria composition stable under strong acidic conditions | |
| CN113598285A (en) | Traditional Chinese medicine fermented feed for improving intestinal immunity of aquaculture animals and preparation method thereof | |
| KR100513167B1 (en) | Acid tolerant probiotic Enterococcus faecalis Probio-053 that can suppresses the growth of pathogenic microorganisms and Salmonella gallinarum | |
| KR100351177B1 (en) | Isolation of novel Lactobacillus fermentum YL-3 | |
| KR100523255B1 (en) | Acid tolerant probiotic Enterococcus faecium Probio-048 that can suppresses the growth of pathogenic microorganisms and Salmonella gallinarum | |
| CN110628683A (en) | Probiotic compound live bacterium preparation for preventing and treating chicken diarrhea and preparation method thereof | |
| Pavithra et al. | Probiotics–A Miracle in Periodontal Therapy | |
| CN109549957A (en) | The compound probiotic of energy bidirectional modulation constipation | |
| CN116676230B (en) | Bifidobacterium animalis capable of utilizing pullulan and application thereof | |
| CN116790402B (en) | Bacteroides simplex strain with anti-inflammatory property, culture method and application | |
| Al-Faragi et al. | Effect of local probiotic on common carp Cyprinus carpio growth performance and survival rate | |
| Guo et al. | Comparative evaluation of three Lactobacilli with strain-specific activities for rats when supplied in drinking water |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191231 |